- Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial Reuters
- Cancer treatment could face landmark moment with promising vaccine The Washington Post
- VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results Reuters
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Business Wire
Рекомендовані коментарі
Для публікації повідомлень створіть обліковий запис або авторизуйтесь